BioSpace News Archive

Marker Therapeutics, Inc. announced today that the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “ neldaleucel ” as the nonproprietary (generic) name for MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product candidate for the treatment of patients with lymphoma.

YPrime today announced a bold brand evolution initiative that articulates its commitment to provide cutting-edge solutions focused on delivering streamlined and accelerated clinical trials, increasing certainty from study design to data lock.

60 Degrees Pharmaceuticals, Inc. announced that, following a Type C meeting held on January 17, 2024 with the US Food and Drug Administration, the Company will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S.

Centessa Pharmaceuticals plc today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim’s 6th Annual Biotechnology Conference Date: February 7, 2024 Location: NY, NY Fireside Chat: 9:00 AM ET.

CalciMedica, Inc. announced that it has entered into a securities purchase agreement with new and existing investors to raise up to approximately $55 million in gross proceeds that includes initial upfront funding of $20.4 million and up to an additional approximately $34.2 million upon exercise of accompanying warrants.

Seelos Therapeutics, Inc. today announced the receipt of minutes from its End of Phase II Meeting with the FDA.

Meru Health published a randomized controlled trial in collaboration with Stanford University, Harvard University , and University of Louisville today in the Journal of Affective Disorders confirming the utility of therapist-supported holistic digital mental health interventions in reducing depression and anxiety symptoms, insomnia, and associated health burdens.

Establishment Labs Holdings Inc. today announced it has launched Motiva ® Implants in China.

INOVIO today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP).

Spruce Biosciences, Inc. today announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).